Market reactionShares fell 11% on Nov 5.
Candel Therapeutics is a clinical-stage company developing viral immunotherapies for cancer, led by aglatimagene for localized prostate cancer; none of its products is approved.
Candel's case rests on aglatimagene, an adenovirus injected into the prostate that, with the oral prodrug valacyclovir, kills tumor cells and primes an immune response. In a randomized, placebo-controlled Phase 3 trial of 745 men having radiotherapy, it improved prostate cancer-specific disease-free survival by 39% at a median of 58 months. Candel plans to file a BLA in the fourth quarter of 2026. A Phase 3 in lung cancer started in June. Cash of $201.6 million lasts into the first quarter of 2028.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: The prostate cancer BLA goes in on schedule
Does Candel submit a complete BLA for localized prostate cancer by the end of 2026?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Candel plans to file its prostate cancer BLA for aglatimagene in Q4 2026
CAN-2409 pursues BLA submission in localized prostate cancer and Phase 3 in ICI-resistant NSCLC; approval and commercial execution are the conditions that determine value
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Lung cancer, Gastrointestinal cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
16 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.